Young S, Chaplin D. September 2004
Combretastatin A4 phosphate: background and current clinical status.
Expert Opin. Investig. Drugs. 13(9):1171-82

Siemann D, Chaplin D, Horsman MR. June 15, 2004
Vascular-Targeting Therapies for Treatment of Malignant Disease.
Cancer. 100(12):2491-9

West CML, Price P. March 2004.
Combretastatin A4 phosphate.
Anti-cancer Drugs. 15(3):179-87

Thorpe PE, Chaplin DJ, Blakeley DC. March 1, 2003
The First International Conference on Vascular Targeting: Meeting Overview.
Cancer Research. 63:1144-1147.

Chaplin DJ, Hill SA. Overview. 2002
Selective Induction of tumor ischemia; Development of vascular targeting agents for cancer therapy.
Current Opinion in Investigational Drugs. 3(9):1381-1384.

Chaplin DJ, Hill SA. December 1, 2002
The development of CA4P as a Vascular Targeting Agent.
Internation Journal of Radiation Oncology Biology Physics 54(5):1472.

Bibby MC. May 2002
Combretastatin anticancer drugs.
Drugs of the Future. 27(5):475-80.

Tozer GM, Kanthou C, Parkins CS, Hill SA. February 2002
The biology of combretastatins as tumour vascular targeting agents.
International Journal of Experimental Pathology 83(1):21-38

Griggs J. February 2001
Targeting tumour vasculature: the development of Combretastatin A-4.
The Lancent Oncology 2:82-7